Your browser doesn't support javascript.
loading
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
Martin, Miguel; Ramos-Medina, Rocio; Bernat, Rebeca; García-Saenz, Jose Angel; Del Monte-Millan, Maria; Alvarez, Enrique; Cebollero, Maria; Moreno, Fernando; Gonzalez-Haba, Eva; Bueno, Oscar; Romero, Paula; Massarrah, Tatiana; Echavarria, Isabel; Jerez, Yolanda; Herrero, Blanca; Gonzalez Del Val, Ricardo; Lobato, Nerea; Rincon, Patricia; Palomero, Maria Isabel; Marquez-Rodas, Ivan; Lizarraga, Santiago; Asensio, Fernando; Lopez-Tarruella, Sara.
Afiliación
  • Martin M; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain. mmartin@geicam.org.
  • Ramos-Medina R; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain.
  • Bernat R; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain.
  • García-Saenz JA; Department of Medical Oncology, Hospital Clínico San Carlos, CIBERONC, Madrid, Spain.
  • Del Monte-Millan M; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain.
  • Alvarez E; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain.
  • Cebollero M; Department of Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Moreno F; Department of Medical Oncology, Hospital Clínico San Carlos, CIBERONC, Madrid, Spain.
  • Gonzalez-Haba E; Pharmacy Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Bueno O; Radiodiagnosis Department, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain.
  • Romero P; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain.
  • Massarrah T; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain.
  • Echavarria I; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain.
  • Jerez Y; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain.
  • Herrero B; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain.
  • Gonzalez Del Val R; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain.
  • Lobato N; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain.
  • Rincon P; Gynecology Department, Hospital General Universitario Gregorio Marañón, IiSGM, Universidad Complutense, Madrid, Spain.
  • Palomero MI; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain.
  • Marquez-Rodas I; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain.
  • Lizarraga S; Gynecology Department, Hospital General Universitario Gregorio Marañón, IiSGM, Universidad Complutense, Madrid, Spain.
  • Asensio F; Experimental Medicine and SurgeryUnit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Lopez-Tarruella S; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Universidad Complutense, Dr Esquerdo 46, 28007, Madrid, Spain.
Sci Rep ; 11(1): 7064, 2021 03 29.
Article en En | MEDLINE | ID: mdl-33782404
Triple-negative breast cancer (TNBC) is highly responsive to neoadjuvant polychemotherapy regimens including anthracyclines, taxanes, and, more recently, carboplatin. However, there is inadequate information on the individual contribution of each of these agents to the global activity of the combinations, and the use of combinations of up to four of these drugs is associated with relevant toxicity. Identifying single-drug activity in the clinical neoadjuvant setting is challenging. We developed patient-derived xenografts (PDXs) from several chemotherapy-naïve TNBC samples to assess the antitumor activity of single drugs and combinations of drugs. PDXs were established from chemotherapy-naïve TNBC samples. Nine TNBC PDX models (all of which corresponded to a basal-like phenotype according to the PAM50 classifier) were treated with carboplatin, docetaxel, and doxorubicin and the combination of docetaxel and carboplatin. Only one of nine PDX models showed sensitivity to doxorubicin, while eight of nine PDX models showed sensitivity to docetaxel and carboplatin as single agents. The 3 PDX models derived from patients with gBRCA-1 or gPALB2 mutations were very sensitive to carboplatin single agent. All 6 PDX models from patients without hereditary germ-line mutations showed increased sensitivity to the combination of docetaxel and carboplatin. In the present study, docetaxel and carboplatin single agents were active drugs against basal-like TNBC, while doxorubicin monotherapy showed low activity. The combination of docetaxel and carboplatin was more effective than the drugs used as single agents, except in the PDX from patients with gBRCA1/PALB2 mutations.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Mama Triple Negativas Límite: Animals / Female / Humans Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Mama Triple Negativas Límite: Animals / Female / Humans Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido